Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts.
Provost K, Iaccarino L, Soleimani-Meigooni DN, Baker S, Edwards L, Eichenlaub U, Hansson O, Jagust W, Janabi M, La Joie R, Lesman-Segev O, Mellinger TJ, Miller BL, Ossenkoppele R, Pham J, Smith R, Sonni I, Strom A, Mattsson-Carlgren N, Rabinovici GD; Alzheimer’s Disease Neuroimaging Initiative (ADNI).
Provost K, et al.
Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2259-2271. doi: 10.1007/s00259-020-05152-8. Epub 2021 Jan 4.
Eur J Nucl Med Mol Imaging. 2021.
PMID: 33398408
Free PMC article.
PURPOSE: To compare rates of tau biomarker positivity (T-status) per the 2018 Alzheimer's Disease (AD) Research Framework derived from [(18)F]flortaucipir (FTP) PET visual assessment, FTP quantification, and cerebrospinal fluid (CSF) phosphorylated Tau-181 (PTau181). ...CO …
PURPOSE: To compare rates of tau biomarker positivity (T-status) per the 2018 Alzheimer's Disease (AD) Research Framework derived from [(18) …